0.73

2.82% 0.02

After Hours: .74 0.01 +1.37%

Neurosense Therapeutics Ltd (NRSN)

Overview News Price History Discussions Forecast

Neurosense Therapeutics Ltd stock is traded at $0.73, with a volume of 109.34K. It is up +2.82% in the last 24 hours and down -15.06% over the past month. NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Previous Close:

$0.71

Open:

$0.71

24h Volume:

109.34K

Relative Volume:

0.57

Market Cap:

$24.38M

Revenue:

Net Income/Loss:

$-10.21M

P/E Ratio:

-1.2496

EPS:

-0.5842

Net Cash Flow:

1W Performance:

+1.25%

1M Performance:

-15.06%

6M Performance:

-41.13%

1Y Performance:

-31.13%

1-Day Range:

$0.71

$0.7499

1-Week Range:

$0.6839

$0.7499

52-Week Range:

$0.63

$2.60

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name

Neurosense Therapeutics Ltd

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-04-06

Latest SEC Filings

NRSN's Discussions on Twitter

Compare NRSN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRSN Neurosense Therapeutics Ltd	0.73	23.71M	0	-10.21M	0	-0.5842
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Neurosense Therapeutics Ltd Stock (NRSN) Latest News

Apr 13, 2026

Form 20-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)] - ADVFN

Apr 13, 2026

Sentiment Review: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesPortfolio Gains Summary & Community Verified Swing Trade Signals - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Nasdaq Moves: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn

Apr 12, 2026

Patterns Watch: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETF2026 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn

Apr 12, 2026

Apr 10, 2026

If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan

Apr 10, 2026

Apr 09, 2026

Trend Report: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingWeekly Risk Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Apr 09, 2026

Bank Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingMarket Weekly Review & Daily Stock Trend Reports - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Chipmakers Recap: Why is NeuroSense Therapeutics Ltd stock going downEarnings Growth Summary & Weekly Market Pulse Alerts - baoquankhu1.vn

Apr 08, 2026

Aug Highlights: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectations2026 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn

Apr 08, 2026

NRSN Analyst Rating Update: D. Boral Capital Maintains 'Buy' Rat - GuruFocus

Apr 08, 2026

Inflation Data: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowEarnings Summary Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Apr 08, 2026

Volatility Watch: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leaders2026 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Apr 08, 2026

Breakout Watch: Is NeuroSense Therapeutics Ltd gaining market share2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo

Apr 07, 2026

Income Plays: Is NeuroSense Therapeutics Ltd stock a value trap2026 AllTime Highs & Short-Term Trading Opportunity Alerts - baoquankhu1.vn

Apr 07, 2026

Is NeuroSense Therapeutics Ltd stock a buy or sellMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

NeuroSense granted Brazilian patent covering PrimeC composition - TipRanks

Apr 06, 2026

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - marketscreener.com

Apr 06, 2026

NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC - TipRanks

Apr 06, 2026

NeuroSense Granted Brazilian Patent Covering PrimeC Composition - Bitget

Apr 06, 2026

Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN

Apr 06, 2026

Apr 04, 2026

NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status - The Globe and Mail

Apr 04, 2026

NRSN PE Ratio & Valuation, Is NRSN Overvalued - Intellectia AI

Apr 04, 2026